|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-06 | Stocks mixed as weak miners weigh in muted trade | AN |
| 07-06 | HSBC Upgrades GSK to Hold Rating, Boosts PT | MT |
| Market Cap | 79.02B 106B 92.42B 85.13B 150B 10,066B 152B 1,019B 397B 4,941B 396B 388B 17,131B | P/E 2026 * |
12.7x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 94.45B 126B 110B 102B 179B 12,032B 182B 1,218B 474B 5,906B 474B 463B 20,477B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.56x |
| Free-Float |
92.29% | Yield 2026 * |
3.51% | Yield 2027 * | 3.7% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.08% | +3.32% | +60.34% | +174.11% | 1,070B | |
| +3.34% | +5.71% | +72.91% | +68.59% | 624B | |
| +1.14% | +2.43% | +37.37% | +90.22% | 450B | |
| +2.09% | -2.07% | +27.62% | +22.57% | 328B | |
| +2.15% | +2.20% | +41.03% | +42.53% | 292B | |
| +1.35% | +0.22% | +29.97% | +49.41% | 284B | |
| +1.98% | +4.08% | -25.78% | -39.02% | 217B | |
| +0.80% | +2.29% | +26.44% | +69.41% | 198B | |
| +3.74% | +7.05% | +20.99% | +81.73% | 161B | |
| Average | +2.22% | +0.98% | +32.32% | +62.17% | 402.71B | |
| Weighted average by Cap. | +2.44% | +0.70% | +44.00% | +88.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.86B 45.23B 39.61B 36.48B 64.31B 4,314B 65.18B 437B 170B 2,118B 170B 166B 7,342B | 35.59B 47.53B 41.63B 38.34B 67.59B 4,534B 68.5B 459B 179B 2,226B 179B 175B 7,716B |
| Net income | 6.47B 8.65B 7.57B 6.97B 12.29B 825B 12.46B 83.48B 32.49B 405B 32.47B 31.75B 1,403B | 6.94B 9.27B 8.12B 7.48B 13.18B 884B 13.35B 89.48B 34.82B 434B 34.8B 34.04B 1,504B |
| Net Debt | 15.43B 20.61B 18.05B 16.62B 29.3B 1,966B 29.7B 199B 77.45B 965B 77.4B 75.7B 3,346B | 12.24B 16.34B 14.31B 13.18B 23.24B 1,559B 23.55B 158B 61.41B 765B 61.37B 60.03B 2,653B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
